Natural Extracts and Bioactive Derivatives: Strategies for Biopharmaceutical Uses

A special issue of Sci (ISSN 2413-4155). This special issue belongs to the section "Biology Research and Life Sciences".

Deadline for manuscript submissions: closed (20 January 2023) | Viewed by 4671

Special Issue Editors

E-Mail Website
Guest Editor
Institute of Neurophysiopathology (INP), Aix-Marseille University, Faculté des sciences médicales et paramédicales, 27, Bd Jean Moulin, 13005 Marseille, France
Interests: antimicrobial peptides; antibacterial; antibiotics; structure-activity relationships; bacteriocins; drug design; peptide engineering
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Faculty of Sciences 3, Lebanese University, Michel Slayman Tripoli Campus, Ras Maska 1352, Lebanon
Interests: drug design; animal venom enzymes; biomolecules; venoms and toxins; biopharmaceuticals
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear colleagues,

For millennia, natural extracts have been known to treat human diseases and are an important source of medicines. To this day, many people around the world still use traditional drugs extracted from plants or animal secretions. Plant essences largely dominate those of animals in this area. Indeed, many drugs are derived from plants and are currently marketed. As for animal extracts, they are also gradually positioning in the pharmaceutical market. Animal venoms and their bioactive molecules are the subject of intense scientific research, and many patents in the field have been awarded. The therapeutic value of animal venoms depends on their use at appropriate doses or encapsulation/formulation in suitable vesicles in order to enable them to enter into the target cells or to minimize their cytotoxicity, if any. The potential synergistic effects of molecules derived from natural extracts have been widely demonstrated. Such synergy between compounds deserves to be examined in more depth by researchers in the coming years.

This Special Issue titled “Natural Extracts and Bioactive Derivatives: Strategies for Biopharmaceutical Uses” consists of a collection of original research and review articles concerning new advances in (i) the discovery, development and application of natural extracts in biopharmaceuticals; (ii) the potential of molecules derived from natural extracts in various fields of research; (iii) the synergy between such natural compounds for greater beneficial effects; and (iv) strategies for rectifying the activity of the biomolecules. The topics of interest for articles include the activities of crude extracts, the bio-guidance of a valued fractionation and the characterization of new value-added biomolecules. The targeted biological properties include antioxidant, antimicrobial, anticancer, and other effects.

Dr. Jean-Marc Sabatier
Prof. Ziad Fajloun
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Sci is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • Bioactive molecules
  • Venom derivatives
  • Plant extracts
  • Anticancer
  • Antimicrobial
  • Toxins
  • Enzymes extracted
  • Natural medicines

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


11 pages, 1152 KiB  
Montivipera bornmuelleri Venom: Inhibitory Effect on Staphylococcus epidermidis and Escherichia coli F1F0-ATPases and Cytotoxicity on HCT116 Cancer Cell Lines
by Milena Kfoury, Charbel Mouawad, Mariam Rifi, Riyad Sadek, Jean-Marc Sabatier, Hala Nehme and Ziad Fajloun
Sci 2021, 3(3), 31; - 14 Jul 2021
Cited by 1 | Viewed by 3698
In this work, we pursued the biological characterization of the venom of Montivipera bornmuelleri, a viper from the Lebanese mountains. In relation to its antibacterial potential, the inhibitory effect of this venom on the F1F0-ATPase enzymes of Gram-positive [...] Read more.
In this work, we pursued the biological characterization of the venom of Montivipera bornmuelleri, a viper from the Lebanese mountains. In relation to its antibacterial potential, the inhibitory effect of this venom on the F1F0-ATPase enzymes of Gram-positive Staphylocoocus epidermidis and Gram-negative Escherichia coli bacteria was examined. In order to determine the degree of cytotoxicity of the venom on the HCT116 human colon cancer cell lines, the biological MTT proliferation and cell viability test were implemented. After validation of the enzymatic F1F0-ATPase model by the spectrophotometric method, using quercetin as the reference ligand, results revealed that M. bornmuelleri venom is able to inhibit the activity of the enzyme of these two bacteria with a concentration of the order of 100–150 µg/mL. In addition, a venom concentration of 10 µg/mL was sufficient to kill the totality of HCT116 cell lines cultivated in vitro. These data show that M. bornmuelleri venom is a mixture of diverse molecules presenting activities of interest, and is a potential source to explore in order to discover new drug candidates. Full article
Show Figures

Figure 1

Back to TopTop